Patricia Pérez-Galán

Grup de recerca

Microambient en la patogènesi i teràpia del limfoma Group leader (R4)

pperez@recerca.clinic.cat 0000-0003-3895-5024

Segueix-lo/a a:

El perfil de ResearchGate de Patricia . Aquest enllaç s'obre en una nova pestanya.

Publicacions destacades

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Autors:
Vidal-Crespo, Anna; Matas-Cespedes, Alba; Rodriguez, Vanina; Rossi, Cedric; Valero, Juan G;

(...)

Bezombes, Christine; van Bueren, Jeroen Lammerts; Chiu, Christopher; Doshi, Parul; Perez-Galan, Patricia.

Referència: Haematologica 2020.
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Autors:
Castella, Maria; Boronat, Anna; Martin-Ibanez, Raquel; Rodriguez, Vanina; Sune, Guillermo;

(...)

Yague, Jordi; Perez-Galan, Patricia; Rives, Susana; Delgado, Julio; Juan, Manel.

Referència: Molecular Therapy-Methods & Clinical Development 2019.
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia

Autors:
Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML;

(...)

Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D .

Referència: International Journal Of Cancer 2019.
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma

Autors:
Rossi C; Gravelle P; Decaup E; Bordenave J; Poupot M;

(...)

Klein C; Céspedes AM; Perez-Galan P; Fournié JJ; Bezombes C.

Referència: Oncoimmunology 2019.
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Autors:
Vidal-Crespo, Anna; Rodriguez, Vanina; Matas-Cespedes, Alba; Lee, Eriong; Rivas-Delgado, Alfredo;

(...)

Lopez-Guillermo, Armando; Lopez-Guerra, Monica; Roue, GaeL; Colomer, Dolors; Perez-Galan, Patricia.

Referència: Haematologica 2017.
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

Autors:
Matas-Cespedes, Alba; Vidal-Crespo, Anna; Rodriguez, Vanina; Villamor, Neus; Delgado, Julio;

(...)

Wiestner, Adrian; Parren, Paul W H I; Doshi, Parul; van Bueren, Jeroen Lammerts; Perez-Galan, Patricia.

Referència: Clinical Cancer Research 2017.
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

Autors:
Matas-Cespedes, Alba; Rodriguez, Vanina; Kalko, Susana G; Vidal-Crespo, Anna; Rosich, Laia;

(...)

Campo, Elias; Roue, Gael; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.

Referència: Clinical Cancer Research 2014.
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Autors:
Herman, S E M; Sun, X; Mcauley, E M; Hsieh, M M; Pittaluga, S;

(...)

Buggy, J J; Aue, G; Tisdale, J F; Perez-Galan, P; Wiestner, A.

Referència: Leukemia 2013.
ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress

Autors:
Chapman, Colby M; Sun, Xiameng; Roschewski, Mark; Aue, Georg; Farooqui, Mohamed;

Stennett, Lawrence; Gibellini, Federica; Arthur, Diane; Perez-Galan, Patricia; Wiestner, Adrian.

Referència: Clinical Cancer Research 2012.
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

Autors:
Herishanu Y; Pérez-Galán P; Liu D; Biancotto A; Pittaluga S;

(...)

White T; Marti G; Munson P; Wilson W; Wiestner A.

Referència: Blood 2011.

Projectes destacats

1. Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO). Funding agency: POCTEFA-INTERREG. EFA123/1. Duration 2024-2026. Role: PI and coordinator.

Codi: EFA 123/1

Durada: 01/01/2024
Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Investigador/a principal: Patricia Pérez Galán

Finançador: Janssen Pharmaceuticals

Durada: 01/01/2020 - 31/12/2020
Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Investigador/a principal: Maria Cinta Cid Xutgla, Patricia Pérez Galán

Finançador: Ministerio de Economia y Competitividad (MINECO)

Codi: SAF 2017- 88275-R

Durada: 01/01/2018 - 31/12/2020
Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Investigador/a principal: Patricia Pérez Galán

Finançador: INTERREG V-POCTEFA

Codi: EFA281/16

Durada: 01/01/2018 - 31/12/2021
Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Investigador/a principal: Patricia Pérez Galán

Finançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Ministerio de Economia y Competitividad (MINECO) ; PROYECTOS I+D+I RETOS INVESTIGACIÓN (Programa financiador competitivo)

Codi: SAF2014-57708-R

Durada: 01/10/2015 - 30/09/2018

Patricia Pérez-Galán

Grup de recerca

Publicacions destacades

Projectes destacats

1. Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO). Funding agency: POCTEFA-INTERREG. EFA123/1. Duration 2024-2026. Role: PI and coordinator.

Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Subscriu-te a la Newsletter del Clínic